Q1 2023 Cytokinetics Inc Earnings Call Transcript
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' First Quarter 2023 Conference Call.
At this time, I would like to inform you that this call is being recorded. (Operator Instructions)
I will now turn the call over to Diane Weiser, Cytokinetic's Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Fady Malik, EVP of R&D, will provide updates related to aficamten and other drug candidates comprising our early-stage pipeline. Stuart Kupfer, SVP and Chief Medical Officer, will provide further updates on the development program for aficamten. Andrew Callos, EVP and Chief Commercial Officer, will speak further about commercial preparation activities for aficamten and the market opportunity. Robert Wong, VP and Chief Accounting
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |